Avalyn Pharma AVLN

On September 15, 2026 the Board of Directors of Avalyn Pharma Inc. the Board appointed Robert Meyer, M.D. to the Board as a Class II director. From January 2018 to October 2024, Dr. Meyer was a principal of the Drug and Biologic Products team at Greenleaf Health Inc., a U.S. Food and Drug Administration, or FDA, strategic consulting company (later acquired by Eliquent Life Sciences). He was an associate professor of Public Health Sciences at the University of Virginia School of Medicine from March 2013 to December 2017, where he also served as the director of the Virginia Center for Translational and Regulatory Sciences. Prior to joining the faculty at the University of Virginia, Dr. Meyer joined Merck & Co., Inc. in October 2007 and served as Vice President and Head of Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories from November 2009 until January 2013. Prior to Merck, Dr. Meyer worked for the FDA from 1994 to 2007, where he was Director of the Division of Pulmonary and Allergy Drug Products from 1999-2002 and Director of the Office of Drug Evaluation II in the Center for Drug Evaluation and Research from 2002-2007. Dr. Meyer holds a B.A. in natural sciences from Lehigh University and an M.D. from the University of Connecticut School of Medicine, where he also completed his residency in internal medicine and served as chief medical resident. He completed a fellowship in pulmonary and critical care medicine at the University of Vermont. Dr. Meyer also formerly served on the board of directors of Chimerix, Inc. (sold to Jazz Pharmaceuticals) from 2018 to 2025, Translate Bio (acquired by Sanofi Inc.) from 2019 to 2021 and Correvio Pharma Corp. from 2015 to 2020. He was a medical science trustee for the United States Pharmacopeia Board, a non-profit scientific standards setting foundation, from April 2015 until December 2020.

Mr. Golden has served as our General Counsel since April 2026. Prior to joining us, Mr. Golden served as a Partner and Global Head of Life Sciences at Freshfields, a leading global law firm, from May 2021 to April 2026. At Freshfields, Mr. Golden founded and oversaw the build-out of an internationally recognized life sciences practice. From February 2014 to May 2021, Mr. Golden served as a Partner and Head of the New York Corporate Practice Group at Hogan Lovells. Mr. Golden began his career at Kaye Scholer where he spent over twenty years and had roles of increasing responsibility, including Partner and Co-Chair, Corporate Department. Throughout his career, Mr. Golden has served as a strategic legal and business adviser to biotechnology, pharmaceutical and other life sciences companies, with a focus on mergers and acquisitions, complex collaborations and other transformative transactions. Mr. Golden serves on the Board of Advisors of Life Sciences Cares. He holds a J.D. from New York University School of Law and an A.B. in Chemistry from Princeton University.

Mr. Congleton has been a member of our board of directors since April 2026. Mr. Congleton has nearly 40 years of pharmaceutical experience in cardiovascular, gastrointestinal, and central nervous system companies with a focus on providing solutions for patients and their caregivers. Mr. Congleton has served as the Chief Executive Officer and a member of the board of directors of Mineralys Therapeutics, Inc. (Nasdaq: MLYS), or Mineralys, a clinical-stage biopharmaceutical company, since November 2020. Prior to joining Mineralys, Mr. Congleton served as the Chief Executive Officer and a member of the board of directors of Impel Pharmaceuticals, or Impel, a commercial-stage drug developer, from September 2017 to May 2020. Prior to Impel, Mr. Congleton served as the Chief Executive Officer and a member of the board of directors of Nivalis Therapeutics, Inc., or Nivalis, a clinical-stage biopharmaceutical company, from January 2015 to February 2017, prior to its merger with Alpine Immune Sciences, Inc. (Nasdaq: ALPN). Prior to Nivalis, Mr. Congleton held positions of increasing responsibility in general management and global strategic marketing at Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), or Teva, from November 1996 to December 2014, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of SANOFI (Nasdaq: SNY), a global healthcare company. Mr. Congleton has served on the board of Immunic, Inc. (Nasdaq: IMUX) since March 2026. Mr. Congleton received his B.S. from Kansas State University in marketing with a minor in microbiology.

Ms. Turner has been the chair of our board of directors since October 2024. Ms. Turner has served as Chief Executive Officer of LB Pharmaceuticals Inc. (Nasdaq: LBRX), a clinical-stage biopharmaceutical company since November 2024. Prior to joining LB Pharmaceuticals, Ms. Turner was President and Chief Executive Officer of Carmot Therapeutics Inc., or Carmot (acquired by Roche) from January 2023 to June 2024 and Chief Operating Officer from September 2022 to December 2022. Prior to Carmot, Ms. Turner served as Chief Legal Officer at Lyell Immunopharma, Inc. from April 2019 to May 2022. Prior to Lyell, Ms. Turner served as Executive Vice President, General Counsel and Secretary of Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a publicly-traded gene therapy and gene editing company, from February 2018 to March 2019, and served as Executive Vice President, General Counsel, Secretary, and Head of Portfolio Strategy at Atara Biotherapeutics, Inc. (Nasdaq: ATRA), or Atara, a publicly-traded allogeneic cell therapy company, from September 2016 to February 2018 and as Vice President and General Counsel of Atara from June 2015 to September 2016. Prior to that, Ms. Turner served as General Counsel and Secretary at Orexigen Therapeutics, Inc. a company focused on metabolic diseases, from June 2007 to June 2015. Ms. Turner has served as a member of the board of directors of Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company, since November 2024. Ms. Turner started her career at Cooley LLP as a corporate securities associate. Ms. Turner received her J.D. from UCLA School of Law and her B.A. in Environmental Studies from the University of California, Santa Barbara.

Ms. Baranowski has served as our President and Chief Executive Officer and as a member of our board of directors since October 2022. Prior to joining us, Ms. Baranowski served as Chief Operating Officer of Altavant, from its formation in October 2018 until October 2022. At Altavant, Ms. Baranowski oversaw the development of therapies for rare respiratory diseases and contributed to the company's $3 billion acquisition by Sumitomo Dainippon in 2019. Prior to Altavant, Ms. Baranowski served as Senior Vice President, Corporate Development & Strategy at Melinta Therapeutics, LLC (formerly, Nasdaq: MLNT) from August 2013 to July 2018. From May 2011 to August 2013, Ms. Baranowski served as Vice President of Commercial Development at Pearl Therapeutics, Inc., which successfully developed a portfolio of inhaled respiratory medicines that led to its $1.15 billion acquisition by AstraZeneca. Ms. Baranowski also served as Vice President at a healthcare-focused venture capital firm based in New York, and served in senior roles in business development, marketing, and public affairs at Novartis Pharmaceuticals in both the U.S. and Switzerland. Throughout her career, Ms. Baranowski has played pivotal roles in the development and commercialization of market-shaping therapies, including BREZTRI, BEVESPI, XOLAIR, TOBI, RECLAST, and BAXDELA, and has helped companies she worked for raise over $750 million in private and public financings. Ms. Baranowski served as a member of the Board of Directors of Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) from November 2021 to May 2023 and serves on the Board of Advisors for Life Science Cares and is a key member of the planning committee for the American Thoracic Society's Respiratory Innovation Summit. Ms. Baranowski holds an M.B.A. from Harvard Business School and a B.A. from American University.

Dr. Rhodes has served as our Chief Operating Officer since September 2023. Prior to joining us, Dr. Rhodes served in various roles at Kriya Therapeutics, Inc. from February 2020 to July 2023, most recently as President & Chief Development Officer, Metabolic Diseases & Neurology. From February 2019 to February 2020, Dr. Rhodes served as Chief Development Officer at Aerami Therapeutics, Inc., which focused on the delivery of inhaled medicines. Dr. Rhodes completed her Ph.D. at Duke University, focusing on pharmacology and toxicology, and is a Diplomate of the American Board of Toxicology and received a B.S. from North Carolina State University.

Ms. Lavelle has been a member of our board of directors since July 2024. From October 2023 until July 2024, Ms. Lavelle served as the Chief Operating Officer and Chief Financial Officer at ProfoundBio, Inc., a private biotechnology company that was acquired by Genmab A/S in May 2024. Prior to ProfoundBio, Ms. Lavelle served as Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.) (Nasdaq: CLYM), a biotechnology company, from October 2020 to March 2023, where she assisted with the company's IPO. From April 2018 to February 2020, Ms. Lavelle served as the Chief Operating Officer at Alder BioPharmaceuticals, Inc., or AlderBio, a Nasdaq-listed biotechnology company that was acquired by H. Lundbeck A/S in October 2019. In addition to that role, she served as Alder's appointed director for Vitaeris Inc., a privately held biotechnology company based in Vancouver, British Columbia, Canada. Prior to that, Ms. Lavelle served in various roles at Amgen Inc. (Nasdaq: AMGN) from 2003 to 2018, most recently serving as General Manager Taiwan from September 2017 to April 2018, as Executive Director, Japan Asia Pacific (Hong Kong) from May 2016 to September 2017, and Executive Director, Global Marketing Business Analytics and Insights from June 2014 to May 2016. Ms. Lavelle has a decade of M&A and licensing experience at Amgen and also led negotiations for the successful sales of two companies (AlderBio and ProfoundBio). She started her career as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle currently serves as a member of several private company boards of directors. She has served as a member of the board of directors of Jade Biosciences, Inc. (Nasdaq: JADE) since September 2024 and served as a member of the board of directors of Neoleukin Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company, which later became Neurogene Inc. (Nasdaq: NGNE), from May 2020 to December 2023. Ms. Lavelle holds a B.A. in economics from Yale University.

Dr. Patel has been a member of our board of directors since March 2017. Dr. Patel serves as a Managing Partner with F-Prime Capital, or F-Prime, where he has worked since 2007. He has worked in the healthcare sector as an investor, consultant, and physician. Prior to joining F-Prime in 2007, Dr. Patel advised biopharmaceutical and medical device companies on brand strategy, clinical development plans, and business development activities in the corporate consulting division of Leerink Swann & Company. Dr. Patel has in the past served as a member of the board of directors of the following entities, each as director of the private company: ABK Biomedical, Aclaris Therapeutics, Inc. (Nasdaq: ACRS), Avivomed, Bicara Therapeutics, Inc. (Nasdaq: BCAX), Caplin Steriles, Comanche Biopharma, Eywa Pharma, Ivenix (acquired by Fresenius Kabi), Laurus Labs (NYSE: LAURUSLABS), Medwell Ventures, Menlo Therapeutics, Inc. (Nasdaq: MNLO), NextWave Pharmaceuticals (acquired by Pfizer), NFlection Therapeutics, Pediatrix Therapeutics, Rallybio Corporation (Nasdaq: RLYB), and Vicept Therapeutics (acquired by Allergan). Dr. Patel holds a B.A. from Rutgers University and an M.D. and M.B.A. from Tufts University School of Medicine. He served as a physician at the VA Boston Healthcare System and at Weill Cornell Medical Center-New York Presbyterian Hospital and Memorial-Sloan Kettering Cancer Center where he completed his internal medicine training.

Dr. Aynechi has been a member of our board of directors since March 2017. Since December 2021, Dr. Aynechi has been a General Partner at Norwest Venture Partners, a venture and growth equity investment firm. Prior to Norwest, from March 2010 through joining Norwest, Dr. Aynechi was a senior partner at Novo Ventures (US) Inc., or Novo Ventures. Prior to joining Novo Ventures, Dr. Aynechi was employed by Burrill & Company, a financial firm specializing in biotechnology and life sciences investment, in various positions, including as a director in merchant banking where she was responsible for regional and cross-border mergers and acquisitions, licensing, and financing transactions. Dr. Aynechi currently serves on the boards of directors of MBX Biosciences (Nasdaq: MBX), Avalyn Pharma, Engrail Therapeutics, Mosanna Therapeutics, Nuvig Therapeutics, Ray Therapeutics and Rezo Therapeutics. She has previously served on various public and private boards of directors including Spruce BioSciences (Nasdaq: SPRB) from May 2016 to December 2025, iRhythm Technologies, Inc. (Nasdaq: IRTC) from May 2014 to April 2017, Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) from October 2018 to August 2021, Nkarta, Inc. (Nasdaq: NKTX) from August 2015 to June 2022, Aristea Therapeutics, Inc. from August 2018 to December 2021 and MDLive Inc. from July 2018 to May 2021. Dr. Aynechi has extensive expertise in the biotechnology and pharmaceutical industries and an illustrious track record of contributing to innovative healthcare solutions. Dr. Aynechi also has experience fostering partnerships that accelerate the development and commercialization of medical therapies. Dr. Aynechi received her Ph.D. in biophysics from the University of California, San Francisco, where her research involved developing computational methods for drug discovery. She received her B.S. in physics from the University of California, Irvine.

Mr. Carlson has served as our Chief Financial Officer and Chief Business Officer since May 2024. Prior to joining us, Mr. Carlson served as the Chief Operating and Financial Officer of Avenge Bio, Inc. from February 2022 to May 2024. Prior to that, he served as Chief Operating and Financial Officer of Ikena Oncology, Inc., or Ikena, (Nasdaq: IKNA) from February 2021 to February 2022 and Chief Financial Officer from January 2019 to February 2021. Prior to Ikena, Mr. Carlson held roles of increasing responsibility at Collegium Pharmaceutical (Nasdaq: COLL), including as Vice President, Commercial Operations, Corporate Strategy & Business Development from March 2013 to January 2019. Prior to joining Collegium, Mr. Carlson was Senior Director of Business Development at BTG International, Inc. (LSE: BTG), or BTG, a publicly-traded, international specialist healthcare company, where he was responsible for global specialty pharmaceutical M&A and licensing, from August 2011 to March 2013. Prior to BTG, Mr. Carlson was Senior Director and Head of Business Development for Lundbeck Inc., or Lundbeck, the U.S. Headquarters of H. Lundbeck A/S, from December 2009 to August 2011. Prior to Lundbeck, Mr. Carlson was Director of Corporate Development and M&A at Ovation Pharmaceuticals, Inc., or Ovation, where he played an integral role in the sale of Ovation to H. Lundbeck A/S in March 2009. Prior to Ovation, Mr. Carlson was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Mr. Carlson began his career in the healthcare investment banking group of Cowen. Mr. Carlson holds a B.A. from Trinity College in Hartford, Connecticut.

Ms. Carroll has been a member of our board of directors since September 2023. Ms. Carroll joined S.R. One Ltd in 2011 and SR One Capital Management, LP in 2020 with a background in biotech partnering and corporate development. Previously, Ms. Carroll completed multiple pharma partnerships and substantial private and public financings for Dynavax Technologies (Nasdaq: DVAX) as the Senior Director, Strategic Planning & Corporate Development. Ms. Carroll was formerly a biopharmaceutical industry consultant with Clearview Projects and Mercer Management Consulting. Currently, Ms. Carroll is on the boards of directors of Arcellx, Inc. (Nasdaq: ACLX), HotSpot Therapeutics, Inc., TBIO, LLC, Odyssey Therapeutics, Inc., Poplar Therapeutics, Inc., and AirNexis Therapeutics, Inc., and previously served on the board of Nkarta, Inc. (Nasdaq: NKTX) from 2017 to 2020. Ms. Carroll received her B.S. in Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.

Ms. Haviland has been a member of our board of directors since March 2026. Ms. Haviland has most recently served as President and Chief Executive Officer of Blueprint Medicines Corporation (formerly Nasdaq: BPMC), or Blueprint, a clinical-stage biopharmaceutical company, from April 2022 through SANOFI's acquisition of Blueprint in July 2025. Prior to serving as President and Chief Executive Officer, Ms. Haviland served as Chief Operating Officer of Blueprint from January 2019 to April 2022 and as Chief Business Officer from January 2016 to January 2019. Prior to joining Blueprint, Ms. Haviland served as vice president, rare diseases and oncology program leadership at Idera Pharmaceuticals, Inc. (acquired by Aceragen, Inc.), a biopharmaceutical company, from April 2014 to December 2015, as head of commercial development at Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a public biopharmaceutical and drug development company, from June 2012 to April 2014, as executive director of commercial development at PTC Therapeutics, Inc. (Nasdaq: PTCT), a public biopharmaceutical company, from March 2007 to June 2012, and roles in corporate development and project management at Genzyme, Inc. (acquired by SANOFI, a global healthcare company) from July 2005 to March 2007. Ms. Haviland has served on the board of directors of Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a public biopharmaceutical company, since June 2018 and as chair of the board of directors since January 2022. Ms. Haviland has also served on the board of directors of Bicara Therapeutics Inc. (Nasdaq: BCAX), a public biotechnology company, since September 2023 and has served as chair of the board of directors of GC Therapeutics, Inc., a private biopharmaceutical company, since December 2025. Ms. Haviland received her M.B.A. from Harvard Business School and her B.A. in Biochemistry/Molecular Biology and Economics from Wesleyan University.

Dr. Hoffman-Luca has served as a member of our board of directors since September 2023. Dr. Hoffman-Luca joined Perceptive Advisors to support the firm's venture fund strategy, including continued investment in companies seeded and incubated at Xontogeny. Since September 2019, she has served as a Partner at Xontogeny, LLC and as Senior Principal, Venture at Perceptive Advisors, LLC, where she assists in managing investments of the Perceptive Xontogeny Venture Funds across the life sciences sector. Prior to joining Perceptive and Xontogeny, Dr. Hoffman-Luca built competitive intelligence capabilities at gene therapy company Solid Biosciences and began her industry career as a patent agent at Choate, Hall & Stewart LLP, where she advised pharmaceutical and academic clients. Dr. Hoffman-Luca currently serves on the board of directors of Adaptilens, Inc., a position she has held since April 2024 and also serves on the boards of directors of CereVasc, Inc. since 2025 and Lonestar Medicines since January 2026. Previously, she served on the board of directors of CARGO Therapeutics, Inc. (formerly Nasdaq: CRGX) from February 2023 to October 2023, prior to its public listing. Dr. Hoffman-Luca earned her Ph.D. in Pharmacology from the University of Michigan Medical School and holds M.S. and B.S. degrees in Chemistry from the University of California, Santa Cruz.

Dr. Lazarus has served as our Chief Medical Officer since August 2023. Dr. Lazarus formerly served as the Chief Medical Officer of Enzyvant Therapeutics, Inc. from December 2022 to July 2023, and Chief Medical Officer of Altavant from February 2020 to November 2022, after its acquisition by Sumitomo Dainippon in 2019. In this role, he was responsible for developing and implementing the clinical development plans for candidates addressing pulmonary arterial hypertension and chronic lung allograft dysfunction. Prior to Altavant, Dr. Lazarus has held senior roles in clinical development and medical affairs teams at Boehringer Ingelheim and Gilead Sciences. Dr. Lazarus holds a B.Sc. and an M.D. from McGill University and he completed his internal medicine training at Boston University. His fellowship training in pulmonary and critical care medicine was obtained at the University of California, San Diego. He is a fellow of the American College of Chest Physicians and a member of the American Thoracic and European Respiratory Societies.

Dr. Friedman has been a member of our board of directors since April 2025. Since January 2020, Dr. Friedman has served as a Managing Director and Senior Analyst at Suvretta Capital Management, LLC, or Suvretta, for its healthcare and biotech-focused Averill investment strategies. Prior to Suvretta, Dr. Friedman was a Healthcare Analyst at Scopia Capital Management from the beginning of 2014 to December 2019 and worked in biotechnology equity research at Morgan Stanley from 2006 to 2009 and 2010 to 2014. Dr. Friedman currently serves on the board of directors of Veradermics, Inc. (Nasdaq: MANE), Click Therapeutics, Inc., and Sapphiros. Dr. Friedman received an M.B.A. from Harvard Business School, an M.D. from University of Pittsburgh School of Medicine and a B.S. from Duke University in Biology.